R&D Views & Analysis | pharmaphorum

Views & Analysis

LEO Pharma’s new R&D lead on driving agility in drug develop...

After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development.

Views & Analysis

Data hackathon analyses truth behind ‘game-changer’ COVID vaccine

COVID-19 underscores need to boost pharma manufacturing in e...

For the past year, life science companies around the world worked at breakneck speed to develop and manufacture safe and effective treatments to respond to the COVID-19 pandemic.

Views & Analysis

Solving the “information challenge” of rare disease diagnosi...

Getting a diagnosis is often the biggest challenge facing a rare disease patient in the UK.

Views & Analysis

Digitalising drug discovery

The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is ver

R&D

Research charity crisis affects the whole development ecosys...

Hopes that the UK government would step in to support charity-funded medical research were dashed when the sector received no mention in the Budget despite campaigns to secure additional su

Views & Analysis

Centessa’s founder on the new company’s unique R&D model

Putting together a quarter-billion dollar pharma company from ten mergers in four months is not for the faint-hearted – but that’s what biotech investment guru Francesco de Rubertis has ach

LEO Pharma’s new R&D lead on driving agility in drug develop...

COVID-19 underscores need to boost pharma manufacturing in e...

Solving the “information challenge” of rare disease diagnosi...

Digitalising drug discovery

Research charity crisis affects the whole development ecosys...

Centessa’s founder on the new company’s unique R&D model

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks